<DOC>
	<DOC>NCT01462604</DOC>
	<brief_summary>This is a 6-week, single arm, pilot study to test the study procedure, educational materials, and measurement instruments for the educational intervention in HER2 overexpressing metastatic or advanced breast cancer patients</brief_summary>
	<brief_title>Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer</brief_title>
	<detailed_description>Approximately 60 subjects with HER2+ metastatic or advanced breast cancer who meet the inclusion/exclusion criteria will be enrolled into the study. All subjects will receive education intervention for 6 weeks including education on Day 0, follow-up phone calls on Day 1 and Day 7, reminder phone calls before Week 3 and 6 visit and telephone hot line number.</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1. Signed written informed consent; 2. Female outpatient aged 18 years or older; 3. Subjects must be about to begin their initial treatment with lapatinib + capecitabine for HER2+ metastatic or advanced breast cancer according to physician's clinical judgement as per local prescribing information 4. Subjects must be literate, be able to read, understand and write local language. 1. Women who is participating in any other interventional clinical trials concurrently; 2. Women who is already taking or had taken lapatinib + capecitabine regimen prior to the enrollment; 3. Primary lesions that are not of breast origin.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>